IP Library › Granted Patent US 10,251,946
Granted Patent B2
US 10,251,946 · App. 15/308,302 · Granted Apr 9, 2019

Anti-microbial immunomodulation

Inventors: Harold David Gunn (Vancouver, CA); Salim Dhanji (North Vancouver, CA); David W. Mullins (Lebanon, NH)
Assignee: Qu Biologics Inc.
A61K39/0266A61K39/0258A61K2039/521A61K2039/54A61K2039/541A61K2039/545A61K2039/55A61K2039/57A61K2039/58Y02A50/474
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,251,946
App. No.
15/308,302
Granted
Apr 9, 2019
Kind
B2
Abstract

The invention provides methods of modulating an immune system in a vertebrate host for the therapeutic or prophylactic treatment of infection by a first microbial pathogen in a target tissue, comprising administration at an administration site of an effective amount of an antigenic formulation comprising antigenic determinants specific for a second heterologous microbial pathogen.

Claims (16)

1. A method of modulating an immune system in a vertebrate host for the prophylactic treatment of infection by a first microbial pathogen in a target tissue, the method comprising:

administering to the vertebrate host an effective amount of an antigenic formulation comprising antigenic determinants specific for a second heterologous microbial pathogen, wherein:

the antigenic determinants are selected from the group consisting of whole cells or cell wall extracts;

the first microbial pathogen is Streptococcus pneumonia or Pseudomonas aeruginosa , the second heterologous microbial pathogen is Klebsiella pneumonia , and the target tissue is the lung; or,

the first microbial pathogen is P. aeruginosa , the second heterologous microbial pathogen is S. aureus , and the target tissue is the skin; or,

the first microbial pathogen is a viral lung pathogen, the second heterologous microbial pathogen is Klebsiella pneumonia , and the target tissue is the lung; and,

wherein the administering comprises administering successive doses of the formulation at a dosage interval of at least one hour, so that two or more doses are administered over a period from 2 days to 1 month, over a dosage duration of at least one week.

2. The method of claim 1 , wherein the host is a human patient.

3. The method of claim 1 , wherein the antigenic determinants comprise whole cells.

4. The method of claim 3 , wherein the whole cells are killed.

5. The method of claim 3 , wherein the whole cells are attenuated.

6. The method of claim 1 , wherein the antigenic determinants comprise cell wall extracts.

7. The method of claim 3 , wherein the host is a human patient.

8. The method of claim 4 , wherein the host is a human patient.

9. The method of claim 5 , wherein the host is a human patient.

10. The method of claim 6 , wherein the host is a human patient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2016
From: GUNN, HAROLD DAVID; DHANJI, SALIM; MULLINS, DAVID W.
To: QU BIOLOGICS INC.
Reel/Frame 040405/0191 →
Continuity (2)
Provisional Application 61988117 · May 2, 2014
Related Publication 20170087237A1 · Mar 30, 2017
Cited By (1)
US 12,491,153